If you deal with chronic migraines, you’re all too familiar with the debilitating pain, sensitivity to bright lights and queasiness that come with them. But what actually causes migraines in the first ...
DEAR DR. ROACH: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...
Dear Dr. Roach: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...
DEAR DR. ROACH: I read your recent column about migraines and strokes. About 40 years ago, I began having occasional visual-interference episodes with zigzags, blurry central vision, and more that ...
March 20 (Reuters) - EyePoint (EYPT.O), opens new tab filed a lawsuit on Friday accusing rival Ocular Therapeutix (OCUL.O), opens new tab of spreading false or misleading information about EyePoint ...
I’ve had the great thrill of seeing the northern lights, both from Alaska and Iceland. But that experience pales next to what I witnessed recently at my favorite coffee shop. I was there for my usual ...
A migraine attack is not just a “bad headache”. Migraine is a debilitating neurological condition which can cause nausea, vomiting, and sensitivity to light or sound, in addition to severe headaches.
Ocular Therapeutix (OCUL) lost ~22% in the premarket on Tuesday after the company released data from a late-stage trial evaluating Axpaxli, its experimental therapy for wet age-related macular ...
Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched position in wet age-related macular degeneration (AMD) with investigational ...
Axpaxli shows modest advantage over Eylea in trial Retinal specialists may value trial data more than investors, analyst says Ocular plans FDA discussions and marketing application The ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results